Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Extracellular Vesicles 2023: Drug Delivery, Biologics & Therapeutics

Hyungtaek Jeon's Biography



Hyungtaek Jeon, Global Product Manager, Xcell Therapeutics Inc.

Education:
Mar. 2009 - Feb. 2014: B.S.
Dept. of Biomedical Laboratory Science, Eulji University. South Korea
Mar. 2014 - Feb. 2018: M.S.& Ph.D. Completion
Dept. of Medicine, Eulji University, South Korea
Mar. 2018 - Feb. 2021: Technical Research Personnel
Dept. of Medicine, Eulji University, South Korea
Mar. 2021: Ph.D.
Dept. of Medicine, Eulji University, South Korea

Dissertation Title:
M.S. & Ph.D. Thesis: “Extracellular Vesicles From KSHV-Infected
Cells Stimulate Antiviral Immune Response Through Mitochondrial DNA.” (Mentor: Myung-Shin Lee, M.D., Ph.D.)

Work Experience:
2014. 3 - 2018. 2:
Research Fellow, Dept. of Medicine, Eulji University, South Korea
2018. 3 - 2021. 2:
Technical Research Personnel (Alternative Military Service), Dept. of Medicine, Eulji University, South Korea
2021.3 - 2023.3
ExoCoBio Inc, South Korea
Department of R&D, Team Exosome engineering, Team leader, South Korea
2023.4 - present
Xcell Therapeutics Inc., South Korea
Department of Sales & Marketing, Global Product Manager, Team leader

Hyungtaek Jeon Image

Animal-Origin-Free Chemically Defined Media for Human MSC and Serum-Free Chemically Defined Media for Exosome Isolation: Revolutionary Advances in Stem Cell and Exosome Research

Thursday, 27 July 2023 at 12:00

Add to Calendar ▼2023-07-27 12:00:002023-07-27 13:00:00Europe/LondonAnimal-Origin-Free Chemically Defined Media for Human MSC and Serum-Free Chemically Defined Media for Exosome Isolation: Revolutionary Advances in Stem Cell and Exosome ResearchExtracellular Vesicles 2023: Drug Delivery, Biologics and Therapeutics in Orlando, FloridaOrlando, FloridaSELECTBIOenquiries@selectbiosciences.com

Xcell Therapeutics introduces two groundbreaking products that aim to revolutionize human mesenchymal stem cell (hMSC) research and exosome isolation. The first product CellCor™ MSC CD AOF is Animal-Origin-Free Chemically Defined Media for Human MSC, which significantly improves cell proliferation, reduces senescence, and demonstrates minimal variation compared to fetal bovine serum (FBS) media and other Chemically defined media.

The second product is a serum-free, chemically defined medium developed for the expansion and isolation of hMSC-derived exosomes called for CellCor™ EXO CD. This innovative medium offers safety, efficiency, stability, and purity, producing higher volumes of extracellular vesicles (EVs) with reduced background particles. Additionally, our novel approach allows for efficient recovery of high-potency exosomes without the need for media change, thereby optimizing exosome collection. Overall, these breakthrough products have the potential to drive advancements in stem cell and exosome research, facilitating discoveries and applications in regenerative medicine and therapeutics.


Add to Calendar ▼2023-07-26 00:00:002023-07-27 00:00:00Europe/LondonExtracellular Vesicles 2023: Drug Delivery, Biologics and TherapeuticsExtracellular Vesicles 2023: Drug Delivery, Biologics and Therapeutics in Orlando, FloridaOrlando, FloridaSELECTBIOenquiries@selectbiosciences.com